antagonist treatment in rats selectively blocks the reflex and afferent responses of vagal lung C fibers to intravenous agonists.
-The terminals of vagal lung C fibers (VLCFs) express various types of pharmacological receptors that are important to the elicitation of airway reflexes and the development of airway hypersensitivity. We investigated the blockade of the reflex and afferent responses of VLCFs to intravenous injections of agonists using perivagal treatment with antagonists (PAT) targeting the transient receptor potential vanilloid 1, P2X, and 5-HT 3 receptors in anesthetized rats. Blockading these responses via perivagal capsaicin treatment (PCT), which blocks the neural conduction of C fibers, was also studied. We used capsaicin, ␣,␤-methylene-ATP, and phenylbiguanide as the agonists, and capsazepine, iso-pyridoxalphosphate-6-azophenyl-2=,5=-disulfonate, and tropisetron as the antagonists of transient receptor potential vanilloid 1, P2X, and 5-HT 3 receptors, respectively. We found that each of the PATs abolished the VLCF-mediated reflex apnea evoked by the corresponding agonist, while having no effect on the response to other agonists. Perivagal vehicle treatment failed to produce any such blockade. These blockades had partially recovered at 3 h after removal of the PATs. In contrast, PCT abolished the reflex apneic response to all three agonists. Both PATs and PCT did not affect the myelinated afferentmediated apneic response to lung inflation. Consistently, our electrophysiological studies revealed that each of the PATs prevented the VLCF responses to the corresponding agonist, but not to any other agonist. PCT inevitably prevented the VLCF responses to all three agonists. Thus these PATs selectively blocked the stimulatory action of corresponding agonists on the VLCF terminals via mechanisms that are distinct from those of PCT. PAT may become a novel intervention for studying the pharmacological modulation of VLCFs.
lung; vagal C fibers; reflex; TRPV1; P2X receptors; 5-HT 3 receptors; perivagal antagonist treatment VAGAL LUNG C-FIBER AFFERENTS play an important role in the regulation of central and local reflex responses, such as bronchoconstriction and cough (5, 30, 53) . Previous investigations suggest that the nerve terminals of these lung afferents may express various types of pharmacological receptors, including transient receptor potential vanilloid 1 (TRPV1) receptors, P2X purinoceptors, and serotonin 5-HT 3 receptors (4, 26, 31, 37, 39, 44, 45, 53, 56) . Using various animal models, there has been increasing interest in exploring the roles of these pharmacological receptors in the activation (4, 26, 33, 45, 56, 60) and sensitization (31, 32, 44) of the vagal lung C fibers, or in the pathogenesis of C-fiber-mediated airway hyperresponsiveness (2, 3, 8, 12, 13, 16, 23, 32, 55) . For example, a recent report has shown that microinjection of opioid into the nodose ganglia amplifies the lung C-fiber-mediated respiratory response to activation of 5-HT 3 receptors (60) . While blockade of these pharmacological receptors is an indispensable intervention in these investigations, the current experimental approaches are not optimal.
Perivagal capsaicin treatment has been widely used as an intervention to study the role of vagal lung C fibers in eliciting reflex changes in breathing patterns (9, 28, 33, 43, 49) , in reflex bronchoconstriction (34, 48) , and in airway hypersensitivity (17, 18) using whole animal models. Capsaicin, a chemical extracted from hot peppers, is an agonist targeting TRPV1 receptors (29) . When capsaicin is applied perineurally to the vagus nerves, the treatment blocks the neural conduction of vagal C fibers (40, 52) and C-fiber-mediated airway responses (9, 17, 18, 33, 34, 43, 48, 49) . However, perivagal capsaicin treatment cannot be used to delineate the specific types of pharmacological receptors involved, because it nonselectively prevents airway responses resulting from activation of a number of different types of pharmacological receptors located at vagal lung C-fiber terminals (33, 43, 49) . In these circumstances, selective blockade of these pharmacological receptors is usually achieved by systemic administration of receptor antagonists (8, 11, 15, 19, 33, 35, 43, 60) . One obvious shortcoming of such systemic treatment is that antagonists may also block pharmacological receptors located at other peripheral sites (i.e., airway smooth muscles) (36, 38, 42) or at central sites (54, 58, 62) , both of which might interfere with the elicitation of C-fiber-mediated airway responses. In other investigations (2, 55) , aerosolized receptor antagonists are delivered into the airways as an alternate method that improves, but does not eliminate, off-target effects compared with systemic administration. Accordingly, an experimental intervention that has no such shortcoming, but is able to delineate the role of specific types of pharmacological receptors in eliciting C-fibermediated airway responses, is needed.
In the peripheral nerves, there is an anterograde intra-axonal transport of transmitter-related substances from the cell body to nerve terminals (7, 47) . Pharmacological receptor antagonists that are applied perineurally to the cervical vagus nerves may possibly be absorbed into the axon and conveyed to the vagal lung C-fiber terminals via the axonal transport system of the vagal afferents. To search for an intervention without the apparent systemic effects of receptor antagonists, we tested the hypothesis that perivagal antagonist treatment may selectively block the reflex and afferent responses of vagal lung C fibers to intravenous injection of the corresponding agonist in rats. To test this hypothesis, the selective blockade by perivagal antagonist treatment of the responses to intravenous agonists of the TRPV1, P2X, and 5-HT 3 receptors was investigated using a well-established rat model (27, 33, 45) . These three types of pharmacological receptors were chosen because they have been suggested to play important roles in functions of vagal lung C fibers (4, 26, 37, 39, 45, 53) . It is conceivable that, if this hypothesis is accepted, perivagal antagonist treatment may become an innovative intervention in research areas related to pharmacological modulation of vagal lung C fibers.
MATERIALS AND METHODS
Animal preparation. The procedures described below are in accordance with the recommendations found in the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health USA and were approved by the Institutional Animal Care and Use Committee of National Yang-Ming University, Taipei, Taiwan. Male Sprague-Dawley rats were anesthetized with an intraperitoneal injection of chloralose (100 mg/kg; Sigma Chemical, St. Louis, MO) and urethane (500 mg/kg; Sigma) dissolved in a borax solution (2%; Sigma). A polyethylene catheter was inserted into the jugular vein and advanced until the tip was close to the right atrium to allow a bolus injection of pharmacological agents. The right femoral artery and vein were cannulated to allow measurement of the animal's arterial blood pressure and for administration of drugs, respectively. During the course of the experiments, supplemental doses of chloralose (20 mg·kg Ϫ1 ·h Ϫ1 ) and urethane (100 mg·kg Ϫ1 ·h Ϫ1 ) were administered to maintain the abolition of the corneal reflex and of the pain reflex induced by pinching the animal's tail. Body temperature was maintained at ϳ37°C throughout the experiment by means of a servocontrolled heating blanket.
The animal's neck was opened along the midline, and the right or both cervical vagus nerves were carefully isolated from their connective tissues for use in later experiments. A short tracheal cannula was inserted just below the larynx via a tracheostomy. Studies of the reflex responses used rats breathing spontaneously via a tracheal cannula. Respiratory flow was measured using a pneumotachograph coupled to a differential pressure transducer (MP45-12, Validyne, Northridge, CA). The flow signal was integrated by an integrator (model 13-G4615-70, Gould, Cleveland, OH) to give the tidal volume (VT). For the studies of C-fiber activity, rats received a midline thoracotomy, and both vagus nerves were ligated just above the diaphragm to eliminate afferent signals arising from the lower visceral organs. The lungs were then ventilated with a rodent respirator (683, Harvard, South Natick, MA) at a constant volume of 8 ml/kg and a positive end-expiratory pressure of 3 cm H 2O. The frequency of the respirator was set at 50 breaths/min and was kept constant in each experiment. In both types of studies, the tracheal pressure was monitored using a pressure transducer (Validyne MP45-28) via a side tap to the tracheal cannula. All physiological signals were recorded on a chart recorder (Gould TA11) and a tape recorder (Neurocorder DR-890, New York, NY) for later analysis.
Pharmacological agents. For stimulation of vagal lung C fibers, capsaicin (a TRPV1 receptor agonist; 1 g/kg) (29), ␣,␤-methylene-ATP (␣,␤-meATP; a P2X receptor agonist; 15 g/kg) (39), and phenylbiguanide (a 5-HT 3 receptor agonist; 6 g/kg) (29) were separately injected into the vein as a bolus in a volume of 0.1 ml. Each of these injections was then flushed into the right atrium by an injection of 0.4 ml saline. For the perivagal treatment with antagonists, capsazepine (a TRPV1 receptor antagonist; 6 mg/ml) (29) , iso-pyridoxalphosphate-6-azophenyl-2=,5=-disulfonate (iso-PPADS; a P2X receptor antagonist; 10 mg/ml) (20) , tropisetron (a 5-HT 3 receptor antagonist; 15 g/ml) (14) , and capsaicin (for blockade of C-fiber conduction; 250 g/ml) (40, 52) were used. The stock solutions of capsaicin (250 g/ml) and capsazepine (10 mg/ml) were prepared by dissolving the chemicals in saline containing 10% Tween 80 and 10% ethanol. The stock solutions of ␣,␤-meATP (2 mg/ml), and phenylbiguanide (2 mg/ml), iso-PPADS (50 mg/ml), and tropisetron (1 mg/ml) were prepared by dissolving the chemical in saline. Solutions of these drugs were prepared daily and further diluted by saline to the desired concentrations. Except for iso-PPADS (Tocris, Cookson, Ellisville, MO), all others drugs were purchased from Sigma. The doses of agonists used in this study were adopted from studies reported previously (43, 46) . The concentrations and applications time of perivagal capsaicin treatment were adopted from previous studies showing that the treatment could block the reflex responses to an intravenous injection of capsaicin, but had no effect on the reflex responses to lung inflation (43) . The experimental conditions for perivagal antagonist treatment were determined by a preliminary study demonstrating that the treatment was able to selectively block the reflex responses to an intravenous injection of the corresponding agonist (see RESULTS) .
Perivagal treatment with antagonists or capsaicin. The techniques of perivagal treatment with antagonists or capsaicin were modified from those reported previously (28, 43) . Briefly, in the studies of reflexes, a segment (ϳ3 mm) of each cervical vagus nerve was wrapped in a cotton strip containing solution of antagonists or capsaicin. A small piece of paraffin film was placed underneath the cotton strip to prevent contact with other tissues and vessels. In the studies of C-fiber activity ( Fig. 1) , the right edge of the neck skin and muscles were ligated and retracted to form a trough. The trough was separated into two isolated compartments by a piece of paraffin film. The contact of this paraffin film with surrounding tissues was ensued by gluing it using tissue adhesive (n-butyl cyanoacrylate; 3M, St. Paul, MN). The right vagus nerve was sectioned rostrally and guided to penetrate through a hole on this paraffin film. Liquid paraffin was then instilled into the rostral compartment to cover the nerve. Vaseline was applied to seal the hole in the well to prevent the leak of liquid paraffin. Perivagal treatment with antagonists or capsaicin was performed on a segment of the vagus nerve located in the caudal compartment. A similar procedure was performed as a sham treatment of the vagus nerve, except that the cotton strip contained vehicle only. Fig. 1 . Schematic diagram illustrating the preparation of right vagus nerve for perivagal treatment and nerve recording. After a midline incision in the neck, the right edge of the skin and muscles were ligated and retracted to form a trough. The trough was separated into two isolated compartments by a piece of paraffin film. The vagus nerve was carefully isolated, sectioned rostrally, and guided to penetrate through a hole on this paraffin film. Liquid paraffin liquid was then instilled into the rostral compartment to cover the nerve. A fine afferent filament was then split from the desheathed nerve trunk lying on a platform and placed on a recording electrode. To perform perivagal treatment, a segment of the vagus nerve located at the caudal compartment was wrapped with a cotton strip containing a solution of the antagonist, capsaicin or vehicle. A small piece of paraffin film was placed underneath the cotton strip to prevent contact with tissues and vessels.
Recording of C-fiber activity. Neural activities arising from vagal lung C fibers were recorded using techniques described elsewhere (27) . Briefly, a fine afferent filament of the right vagus nerve was split and placed on a platinum-iridium unipolar recording electrode to record afferent nerve activity (Fig. 1) . The thin filament was further split until the afferent activity arising from a single unit was electrically isolated. Once the presence of a suspected single unit was detected, capsaicin (1 g/kg) was injected as a bolus into the right atrium. Only afferent fibers that showed stimulation within 2 s after the injection were studied. Before the end of each experiment, the general locations of all fibers were identified by their responses to the gentle pressing of the lungs with a saline-wetted cotton Q-tip.
Experimental design and protocols. In this study, 288 rats (weighing 300ϳ380 g) were divided into 39 groups. One series of the studies of reflexes (12 groups; each n ϭ 8) was conducted to assess the selective blockade of agonist-evoked apneic response by perivagal antagonist treatment. The apneic responses to intravenous injection of capsaicin, ␣,␤-meATP or phenylbiguanide, and to lung inflation were investigated before and 30 min after perivagal antagonist treatment with capsazepine, iso-PPADS, or tropisetron. To evoke airway reflex mediated through vagal lung myelinated afferents (5), lung inflation was achieved by inflating the lungs to a tracheal pressure of 10 cmH 2O with a syringe and persisted until the recovery of spontaneous breathing. To avoid possible interaction among TRPV1, P2X, and 5-HT3 receptors, the ventilatory responses to these three agonists before and after perivagal antagonist treatment were studied using three different groups of rats. A second series of the studies of reflexes (3 groups; each n ϭ 8) was conducted to assess the reversibility of blocking effects of perivagal antagonist treatment. The apneic responses to intravenous injection of capsaicin, ␣,␤-meATP, or phenylbiguanide were investigated before; 30 min after perivagal antagonist treatment with capsazepine, iso-PPADS, or tropisetron, and 3 h after removal of the treatment. To facilitate recovery from the treatment, the vagus nerve was washed with warm saline. The third series of the studies of reflexes (12 groups; each n ϭ 8) was conducted to assess the nonselective blockade of agonist-evoked apneic response by perivagal capsaicin treatment. The ventilatory responses to intravenous injection of capsaicin, ␣,␤-meATP, or phenylbiguanide and to lung inflation were investigated before and 30 min after perivagal treatment with capsaicin or vehicle, and after bilateral cervical vagotomy. One series of the electrophysiological study (12 groups; each n ϭ 6) was conducted to assess the selective blockade of agonistevoked C-fiber responses by perivagal antagonist treatment. The afferent responses of vagal lung C fibers to intravenous injections of capsaicin, ␣,␤-meATP, or phenylbiguanide were investigated before and 30 min after perivagal antagonist treatment with capsazepine, iso-PPADS, or tropisetron, and after perivagal capsaicin treatment.
Data analysis and statistics. For the reflex studies, respiratory frequency (f), VT, and expiratory duration (TE) were analyzed on a breath-by-breath basis over an interval of at least 20 breaths before and 60 breaths after agonist injections or lung inflation. The baseline TE was calculated as the average value over the 10-breath period immediately preceding a challenge. To compare the apneic response evoked by different experimental conditions, the longest TE occurring during the first 10 breaths after a challenge was divided by the baseline TE to yield the apneic ratio. For the electrophysiological studies, C-fiber activity was continuously analyzed at 1-s intervals over an interval of at least 20 s before and 60 s after agonist injections. Baseline fiber activity was calculated as the average value over the 10-s period immediately preceding agonist injections. The peak response was defined as the maximum 1-s value during 10 s following agonist injections. In all studies, the heart rate and mean arterial blood , and phenylbiguanide (6 g/kg; a 5-HT3 receptor agonist) were separately injected into the vein as a bolus, as indicated by arrows. Agonist injection was repeated immediately after 30-min of perivagal treatment with capsazepine (6 mg/ml; a TRPV1 antagonist). V R, respiratory flow; VT, tidal volume; ABP, arterial blood pressure. Note that perivagal capsazepine treatment selectively blocked the reflex apneic response to intravenous capsaicin, while having no effect on the response to intravenous ␣,␤-meATP or phenylbiguanide.
pressure were continuously analyzed at 1-s intervals. These physiological parameters were analyzed using a computer equipped with an analog-to-digital converter (Gould DASA 4600) and software (BioCybernatics, 1.0; Taipei, Taiwan). Data from two groups were compared using paired t-tests. Data from three or more groups were compared using one-way or two-way repeated-measures ANOVA, followed by Fisher's test when appropriate. A value of P Ͻ 0.05 was considered significant. All data are presented as means Ϯ SE.
RESULTS
Baseline physiological parameter data. In the studies of reflexes, the mean baseline f and VT values of the 216 rats tested were 71.8 Ϯ 0.9 breaths/min and 1.86 Ϯ 0.03 ml, respectively. In the electrophysiological studies, the 72 vagal lung C fibers recorded from 72 rats had sparse or no activity during the baseline period, and their mean baseline activity was 0.01 Ϯ 0.01 impulses/s. At the beginning of experiments, the mean baseline arterial blood pressure and heart rate values of these 288 rats were 95.3 Ϯ 0.6 mmHg and 380.7 Ϯ 3.0 beats/min, respectively. After completion of the protocol, the mean baseline arterial blood pressure and heart rate values of these rats still maintained at 95.2 Ϯ 0.7 mmHg and 383.6 Ϯ 2.4 beats/min, respectively.
Selective blockade of agonist-evoked apneic response by perivagal antagonist treatment. Figure 2 shows representative tracings of acute ventilatory responses to intravenous injection of capsaicin, ␣,␤-meATP, or phenylbiguanide before and 30 min after perivagal antagonist treatment with capsazepine in three anesthetized rats. As shown, before perivagal antagonist treatment (Fig. 2, left) , injection of each of the agonists immediately (within 1-3 breaths) evoked an apneic response, which was manifested by a prolongation of TE. After perivagal antagonist treatment with capsazepine (Fig. 2, right) , the apneic response to injection of capsaicin was completely prevented, whereas the apneic response to injection of ␣,␤-meATP or phenylbiguanide persisted. Analysis of the group data revealed that the apneic ratios were increased by 7.5-, 9.4-, and 10.3-fold in response to the injection of capsaicin, ␣,␤-meATP, and phenylbiguanide, respectively, before perivagal antagonist treatment (Fig. 3, A-C) . The various types of perivagal treatments did not significantly affect the baseline f and VT (Table 1) . However, perivagal antagonist treatment with capsazepine (Fig. 3, top) prevented the increase in the apneic ratio induced by capsaicin, while having no effect on that induced by ␣,␤-meATP or phenylbiguanide. Similarly, perivagal antagonist treatment with iso-PPADS (Fig. 3, middle) blunted the increase in the apneic ratio induced by ␣,␤-meATP, while having no effect on that induced by capsaicin or phenylbiguanide. Additionally, perivagal antagonist treatment with tropisetron (Fig. 3, bottom) blocked the increase in the apneic ratio induced by phenylbiguanide, while having no effect on Fig. 3 . Effects of perivagal treatment with capsazepine (top), iso-pyridoxalphosphate-6-azophenyl-2=,5=-disulfonate (iso-PPADS; middle), and tropisetron (bottom) on the reflex apneic response to intravenous injection of capsaicin (A), ␣,␤-meATP (B), or phenylbiguanide (C), and to lung inflation (D) in 12 groups of rats. Capsaicin (a TRPV1 agonist), ␣,␤-meATP (a P2X receptor agonist), and phenylbiguanide (a 5-HT3 receptor agonist) were separately injected into the vein as a bolus. Lung inflation was performed by inflating the lungs to a tracheal pressure (Ptr) of 10 cmH2O. Agonist injection or lung inflation was repeated immediately after a 30-min duration of perivagal treatment with capsazepine (6 mg/ml; a TRPV1 antagonist), iso-PPADS (10 mg/ml; a P2X receptor antagonist), and tropisetron (15 g/ml; a 5-HT3 receptor antagonist). The longest expiratory duration (TE) occurring during the first 10 s after agonist injection or lung inflation was divided by the baseline TE to yield the apneic ratio. The horizontal dashed lines indicate an apneic ratio of 1 (no response). *P Ͻ 0.05 vs. response before perivagal treatment. Data in each group are means Ϯ SE of eight rats. Note that perivagal treatment with an antagonist selectively blocked the reflex apneic response to the corresponding intravenous agonist. that induced by capsaicin or ␣,␤-meATP. In contrast to these selective blockades of responses to agonists, perivagal antagonist treatment with each of these three antagonists did not significantly affect the increase in the apneic ratio induced by lung inflation (Fig. 3D) .
Reversibility of blocking effects of perivagal antagonist treatment. To investigate the reversibility of blocking effects, perivagal antagonist treatment was removed after the apneic response to intravenous agonists had been blocked in three additional groups of rats. At 3 h after removal of perivagal antagonist treatment with capsazepine, iso-PPADS, or tropisetron, the apneic response evoked by injection of capsaicin (Fig. 4A) , ␣,␤-meATP (Fig. 4B ), or phenylbiguanide (Fig. 4C) reappeared. Analysis of the group data revealed that the increase in the apneic ratio evoked by capsaicin, ␣,␤-meATP, and phenylbiguanide recovered to 79.1, 48.1, and 54.4%, respectively, of the responses before perivagal antagonist treatment (Fig. 4) .
Nonselective blockade of agonist-evoked apneic responses by perivagal capsaicin treatment. To demonstrate other types of blocking effects for the purpose of comparison, the effects of perivagal capsaicin treatment, perivagal vehicle sham treatment, and bilateral cervical vagotomy were studied in three additional groups of rats. Analysis of the group data revealed that perivagal vehicle sham treatment (Fig. 5, top) did not affect the increase in the apneic ratio induced by intravenous injection of capsaicin, ␣,␤-meATP, or phenylbiguanide, and by lung inflation. Additionally, perivagal capsaicin treatment (Fig.  3, middle) nonselectively blocked the increase in the apneic ratio induced by capsaicin, ␣,␤-meATP, or phenylbiguanide, while having no effect on that induced by lung inflation. Furthermore, vagotomy prevented the increase in the apneic ratio induced by the three agonists tested and by lung inflation.
Selective blockade of agonist-evoked C-fiber response by perivagal antagonist treatment. Figure 6 shows representative tracings of afferent responses of vagal lung C fibers to intravenous injection of capsaicin before and 30 min after perivagal antagonist treatment with capsazepine, iso-PPADS, tropisetron, or capsaicin in four anesthetized, mechanically ventilated rats. As shown, before perivagal antagonist treatment (Fig. 6, left) , injection of capsaicin immediately (within 2 s) evoked an intense burst of C-fiber discharge. The same injection of capsaicin no longer stimulated these lung afferents after perivagal antagonist treatment with capsazepine or perivagal capsaicin treatment, but it still evoked similar afferent responses after perivagal antagonist treatment with iso-PPADS or tropisetron (Fig. 7, right) . Analysis of the group data revealed that, before any perivagal treatment, the peak increases in C-fiber activity evoked by injection of capsaicin, ␣,␤-meATP, and phenylbiguanide were 12.9 Ϯ 0.8, 6.8 Ϯ 0.8, and 7.2 Ϯ 0.4 impulses/s (each n ϭ 24). The various types of perivagal treatments did not significantly affect the baseline C-fiber activity (Fig. 7) . However, perivagal antagonist treatment with capsazepine blocked the increase in C-fiber activity evoked by injection of capsaicin, while having no effect on that evoked by injection of ␣,␤-meATP or phenylbiguanide (Fig. 7, first row) . Similarly, perivagal antagonist treatment with iso-PPADS blunted the increase in C-fiber activity evoked by injection of ␣,␤-meATP, while having no effect on that evoked by injection of capsaicin or phenylbiguanide (Fig. 7, second row) . Additionally, perivagal antagonist treatment with tropisetron prevented the Values are means Ϯ SE; n, no. of rats. f, respiratory frequency; VT, tidal volume. Capsazepine, iso-pyridoxalphosphate-6-azophenyl-2=,5=-disulfonate (iso-PPADS), and tropisetron are antagonists of transient receptor potential vanilloid 1, P2X, and 5-HT3 receptors, respectively. Baseline data were calculated as the average values over the 10-breath period immediately preceding the first intravenous injection of agonists (before perivagal treatment) and the second intravenous injection of agonists (after perivagal treatment). No significant differences were detected when the values before and after perivagal treatment were compared. Fig. 4 . Effects of perivagal treatment with capsazepine, iso-PPADS, and tropisetron on the reflex apneic response to intravenous injection of capsaicin (A), ␣,␤-meATP (B), or phenylbiguanide (C) in three groups of rats. See legend to Fig. 3 for further explanations of pharmacological functions of these drugs and calculation of the apneic ratio. Agonist injection was performed before, immediately after a 30-min duration of perivagal antagonist treatment, and 3 h after removal of perivagal antagonist treatment (Recovery). Facilitation of the recovery from perivagal treatment was achieved by washing the vagus nerve with warm saline. The horizontal dashed lines indicate an apneic ratio ofSelective Blockade by Perivagal Antagonist Treatment • Lin Y et al. increase in C-fiber activity evoked by injection of phenylbiguanide, while having no effect on that evoked by injection of capsaicin or ␣,␤-meATP (Fig. 7, third row) . In contrast to these selective blockades, perivagal capsaicin treatment nonselectively blocked the increase in C-fiber activity evoked by injection of all three agonists tested (Fig. 7, fourth row) .
DISCUSSION
Results of this study demonstrate that perivagal treatment with antagonists of TRPV1, P2X, or 5-HT 3 receptors blocked the apneic response to intravenous injection of the corresponding agonist, while having no effect on the apneic response to other agonists (Fig. 3) . The blockade of these perivagal antagonist treatments seems to be due to the effects of antagonists, because perivagal vehicle sham treatment failed to produce such effects (Fig. 5) . These blockades are reversible after removal of the various perivagal antagonist treatments (Fig. 4) , suggesting that they are unlikely due to the possible deleterious effects of the antagonists tested on the vagus nerve. The support for the selective blockades also comes from the observation that these perivagal antagonist treatments did not affect the apneic response to lung inflation (Fig. 3D) , an airway reflex mediated through vagal lung myelinated afferents (5) . The apneic response to intravenous agonists tested appears to be an airway reflex mediated through vagal lung C fibers, because it was totally prevented by bilateral cervical vagotomy or by perivagal capsaicin treatment (Fig. 5) . Thus it is plausible that the abolition of the reflex apnea by perivagal antagonist treatment was due to the prevention of the agonist-evoked increase in afferent activity arising from vagal lung C fibers. This notion is strongly supported by our findings from the electrophysiological studies, demonstrating that each of the perivagal antagonist treatments tested prevented the lung C-fiber response to intravenous injection of the corresponding agonist, while having no effect on the responses to other agonists (Fig. 7) . Our finding that selectively blocking one type of receptors did not affect the response to activating the other two types of receptors suggests the lack of interaction of these receptors in modulating the reflex and afferent responses mediated by lung C fibers. Collectively, our results show that the perivagal antagonist treatments tested selectively blocked the reflex apneic and afferent responses of vagal lung C fibers to the corresponding agonist.
The exact mechanism by which perivagal antagonist treatment selectively blocked the responses of vagal lung C fibers to the corresponding agonist remains elusive. However, comparisons of blocking effects produced by perivagal antagonist treatment and perivagal capsaicin treatment perhaps might allow us to exclude or include some possibilities. Perivagal capsaicin treatment is known to block the propagation of an action potential along the C-fiber axon without affecting neural conduction in A fibers (40, 52) and, consequently, produces conduction analgesia of C fibers (25) . Thus it is not surprising that the perivagal capsaicin treatment in this study had no effect on the apneic response to lung inflation (Fig. 5) . However, owing to this conduction blockade, perivagal capsaicin treatment nonselectively prevented the reflex (Fig. 5 ) and afferent responses (Fig. 7) of vagal lung C fibers to intravenous agonists of TRPV1, P2X, and 5-HT 3 receptors. Evidently, the results produced by perivagal capsaicin treatment are totally different from those produced by perivagal antagonist treatment, since the latter shows selective blockade of the responses only to the corresponding agonist (Figs. 5 and 7) . Accordingly, blockade of neural conduction cannot be employed to explain the blocking effects of perivagal antagonist treatments observed in this study. Additionally, the conduction blockade of C fibers by perivagal capsaicin treatment involves the agonist effect of capsaicin on TRPV1 receptors located at axonal membrane (25) . Previous studies targeting the response to local application of various agonists suggest that the axonal membrane of the vagus nerve may express TRPV1 (57), P2X (21) , and 5-HT 3 receptors (10). Thus it seems to be possible that the evoked lung C-fiber-mediated response to intravenous agonists results from activation of these receptors on the C-fiber axonal membrane, which are then selectively blocked by perivagal treatment with their corresponding antagonists. However, if that is the case, the C-fiber-mediated response would not be blocked, because the antagonists were locally applied to only a very small segment of cervical vagal trunk. Additionally, the selective blockades of perivagal antagonist treatments we observed are also unlikely to be due to the action of antagonists on these receptors located at the axonal membrane, because the propagation of action potential along the C-fiber axon does not require the function of these pharmacological receptors located at the axonal membrane.
One possible mechanism for blockade by perivagal antagonist treatment is that, although the antagonists were applied perineurally, they still entered the circulation through absorption; they then reached the vagal lung C-fiber terminals and antagonized the action of agonists. This possibility was minimized in our study by prevention of the contact of antagonists with the tissues other than those of the vagus trunk (Fig. 1) . Thus the systemic effect of antagonists produced by perivagal antagonist treatment, if any, should be far smaller than that produced by intravenous injection (8, 11, 15, 19, 33, 35, 43) . The other possibility is that, after absorption into the axon, the antagonists were conveyed to the vagal lung C-fiber terminals via the axonal transport system of the vagal afferents, although the transport rate has been reported to be only a few centimeters per day (47) . Indeed, the peripheral nerves possess an anterograde intra-axonal system for transporting transmitterrelated substances from the cell body to nerve terminals (7, 47). It is worth noting that results from several investigations have suggested that there is a fast intra-axonal transport of transmitter-related substances in addition to the "classic" slow flow (7) . A previous study reported that, when radiolabeled materials are injected into the nodose ganglion, they can be transported in afferent fibers of the vagus nerve at fast transport rates (47) . The mechanisms underlying axonal transport are still largely unclear, but substances in the nerve axon may be stored in or affiliated with certain particles that are dragged along microtubules (7) . To this end, it is known that agonists of TRPV1 receptors bind at putative intracellular sites (41), whereas agonists of P2X and 5-HT 3 receptors bind at extracellular sites (22, 61) . Whether the antagonists might be able to reach the vagal lung C-fiber terminals within the treatment time and be able to antagonize the action of agonists via this route requires further investigation. Whatever the mechanisms may be, the blockade by perivagal antagonist treatment seems to be long lasting, because the blocking effect of the antagonists used in this study did not totally recover at 3 h after treatment.
In addition to TRPV1, P2X, and 5-HT 3 receptors, the vagal lung C-fiber terminals may also express other types of pharmacological receptors, including transient receptor potential ankyrin 1, acetylcholine, bradykinin, dopamine, and adenosine receptors (3, 30, 31, 33, 53) , all of which may also participate in the elicitation of various airway responses. On the other hand, in addition to the lungs, visceral sensory C fibers also play an important role in the pathophysiological regulation of other organs, such as the heart (50), liver (6), bladder (1), and gastrointestinal tract (24, 51, 59 ). Whether the technique of perivagal antagonist treatment can be applied to the study of other pharmacological receptors in the lungs or to investigations targeting the functions of visceral sensory C fibers in organs other than the lungs remains to be investigated in future studies.
In summary, our results show that perivagal treatment with antagonists of the TRPV1, P2X, or 5-HT 3 receptors selectively blocks the stimulatory action of corresponding agonists on vagal lung C-fiber terminals through mechanisms that are distinct from those of perivagal capsaicin treatment. The evidence provided here suggests that perivagal antagonist treatment has the possibility of becoming a novel intervention that can be used to investigate the role of pharmacological receptors in the functioning of vagal lung C fibers, which is an important topic in the study of the pharmacological modulation of C-fiber-mediated airway reflexes and airway hypersensitivity. 
